Nifty
:
15763.05
Sensex
:
52586.84
-15.40 (-0.10%)
-66.23 (-0.13%)
Nifty
Sensex
:
:
15763.05
52586.84
-15.40 (-0.10%)
-66.23 (-0.13%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
37/99

BSE: 524816 | NSE: NATCOPHARM

NSE BSE
1024.05
30-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  1020.00
  •  1036.00
  •  1002.10
  •  1018.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  590417
  •  6017.40
  •  1189.00
  •  731.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,666.83
  • 42.34
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 18,916.73
  • 0.66%
  • 4.53

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.87%
  • 3.21%
  • 16.48%
  • FII
  • DII
  • Others
  • 13.7%
  • 15.28%
  • 2.46%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.34
  • 10.91
  • -4.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.46
  • 16.40
  • -8.90

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.02
  • 24.01
  • -12.85

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.04
  • 26.18
  • 21.15

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.45
  • 5.15
  • 3.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.05
  • 19.70
  • 16.42

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
331.30
454.80
-27.15%
355.20
482.20
-26.34%
802.20
485.70
65.16%
563.40
492.30
14.44%
Expenses
255.10
326.50
-21.87%
272.70
353.50
-22.86%
525.80
351.40
49.63%
392.30
301.00
30.33%
EBITDA
76.20
128.30
-40.61%
82.50
128.70
-35.90%
276.40
134.30
105.81%
171.10
191.30
-10.56%
EBIDTM
23.00%
28.21%
23.23%
26.69%
34.46%
27.65%
30.37%
38.86%
Other Income
28.40
22.40
26.79%
30.80
30.80
0.00%
25.70
33.20
-22.59%
18.70
21.00
-10.95%
Interest
3.50
3.50
0.00%
3.40
5.30
-35.85%
2.70
6.20
-56.45%
3.70
6.50
-43.08%
Depreciation
30.40
30.50
-0.33%
29.80
25.40
17.32%
28.70
21.90
31.05%
28.00
22.00
27.27%
PBT
70.70
116.70
-39.42%
80.10
128.80
-37.81%
270.70
139.40
94.19%
158.10
183.80
-13.98%
Tax
17.70
23.50
-24.68%
16.70
24.40
-31.56%
66.80
21.70
207.83%
36.00
41.00
-12.20%
PAT
53.00
93.20
-43.13%
63.40
104.40
-39.27%
203.90
117.70
73.24%
122.10
142.80
-14.50%
PATM
16.00%
20.49%
17.85%
21.65%
25.42%
24.23%
21.67%
29.01%
EPS
2.90
5.17
-43.91%
3.45
5.74
-39.90%
11.12
6.54
70.03%
6.75
7.87
-14.23%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
459.68
Net Sales Growth
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
13.93%
 
Cost Of Goods Sold
511.40
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
203.08
186.08
Gross Profit
1,540.70
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
273.60
GP Margin
75.08%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
59.52%
Total Expenditure
1,445.90
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
369.11
Power & Fuel Cost
-
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
21.41
% Of Sales
-
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
4.66%
Employee Cost
-
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
66.39
% Of Sales
-
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
14.44%
Manufacturing Exp.
-
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
43.32
40.18
% Of Sales
-
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
8.74%
General & Admin Exp.
-
132.80
126.40
105.50
88.10
73.40
63.66
56.21
39.49
32.37
27.32
% Of Sales
-
6.93%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
5.94%
Selling & Distn. Exp.
-
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
19.02
13.24
% Of Sales
-
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
2.88%
Miscellaneous Exp.
-
66.40
58.70
38.50
71.50
24.10
15.31
9.85
7.36
9.66
13.24
% Of Sales
-
3.47%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
3.15%
EBITDA
606.20
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
90.57
EBITDA Margin
29.54%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
19.70%
Other Income
103.60
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
4.64
Interest
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
14.20
Depreciation
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
15.88
PBT
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
65.12
Tax
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
13.21
Tax Rate
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
20.29%
PAT
442.40
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
53.51
PAT before Minority Interest
440.90
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
51.91
Minority Interest
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
1.60
PAT Margin
21.56%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
11.64%
PAT Growth
-3.43%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
11.40%
 
EPS
24.27
25.28
35.35
38.19
26.66
8.62
7.38
5.64
3.94
3.27
2.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
352.43
Share Capital
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
28.15
Total Reserves
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
324.29
Non-Current Liabilities
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
160.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
125.21
Unsecured Loans
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
0.22
Long Term Provisions
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
8.67
Current Liabilities
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
193.38
Trade Payables
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
76.60
Other Current Liabilities
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
43.86
Short Term Borrowings
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
72.02
Short Term Provisions
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
0.91
Total Liabilities
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
707.31
Net Block
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
270.16
Gross Block
2,148.60
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
374.37
Accumulated Depreciation
564.20
467.30
389.00
325.70
273.20
225.82
171.11
140.57
117.34
104.21
Non Current Assets
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
460.37
Capital Work in Progress
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
75.98
Non Current Investment
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
61.79
Long Term Loans & Adv.
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
66.22
51.49
Other Non Current Assets
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
0.42
0.96
Current Assets
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
246.95
Current Investments
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
0.82
Inventories
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
102.23
Sundry Debtors
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
70.98
Cash & Bank
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
32.37
Other Current Assets
1,121.60
107.40
53.20
25.80
150.80
57.06
56.85
43.14
50.34
40.55
Short Term Loans & Adv.
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
41.84
36.73
Net Current Assets
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
53.56
Total Assets
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21
707.32

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
36.99
PBT
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
65.12
Adjustment
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
36.97
38.87
Changes in Working Capital
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
-48.50
Cash after chg. in Working capital
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
55.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
-18.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
-88.78
Net Fixed Assets
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
-71.49
Net Investments
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
8.04
Others
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
-25.33
Cash from Financing Activity
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
77.10
Net Cash Inflow / Outflow
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
25.31
Opening Cash & Equivalents
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
6.53
Closing Cash & Equivalent
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64
31.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
125.21
ROA
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
8.23%
ROE
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
15.77%
ROCE
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
15.90%
Fixed Asset Turnover
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
Receivable days
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
56.98
50.31
Inventory Days
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
73.13
70.50
Payable days
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
83.93
Cash Conversion Cycle
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
51.07
36.89
Total Debt/Equity
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
Interest Cover
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45
5.59

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Natco Pharma’s marketing partner gets approval for Carfilzomib Vials
    14th Jun 2021, 11:45 AM

    The parties have received final approval for 10mg and 60mg strengths of the product and tentative approval for 30mg strength of the product

    Read More
  • Natco Pharma’s marketing partner receives final approval for Everolimus tablets
    22nd May 2021, 11:42 AM

    NATCO's partner BPI plans to launch 0.25 mg, 0.5 mg and 0.75 mg strengths of the product shortly

    Read More
  • Natco Pharma receives USFDA approval for Lenalidomide Capsules
    22nd May 2021, 11:26 AM

    NATCO and Arrow shall launch the product on agreed-upon launch dates in the future

    Read More
  • Natco Pharma starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment
    22nd May 2021, 09:01 AM

    Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir Capsules in mild COVID-19 patients

    Read More
  • Natco Pharma signs voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India
    17th May 2021, 15:18 PM

    Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India

    Read More
  • Natco Pharma gets emergency use approval from CDSCO for Baricitinib tablets for Covid-19 treatment
    3rd May 2021, 09:18 AM

    The company is ready to launch the product this week, so as to make the product available to suffering patients across India

    Read More
  • Natco Pharma applies to CDSCO for Phase-III clinical trial of Molnupiravir Capsules for Covid-19 treatment
    26th Apr 2021, 09:32 AM

    Pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.